Cord blood boost: new hope for tough myeloma cases?

NCT ID NCT03441958

Completed Disease control Sponsor: Ciusss de L'Est de l'Île de Montréal Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new way to treat high-risk multiple myeloma using umbilical cord blood that was expanded in the lab with a molecule called UM171. Nineteen patients received this special transplant to see if it was safe and could help control the disease. The goal is to improve outcomes while reducing side effects like graft-versus-host disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ECT-001 (UM171) expanded cord blood
What this could lead to: If successful, this approach could offer a safer and more effective transplant option for high-risk multiple myeloma patients, potentially improving long-term disease control.
What could go wrong: This is an early-phase trial with only 19 participants, so results may not apply broadly. Risks include graft-versus-host disease, infections, and disease progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

CIUSSS de l'Est-de-l'île-de-Montréal, Installation Hôpital Maisonneuve Rosemond

Montreal, Quebec, H1T2M4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.